Spatial proteomics guided by H&E-based AI reveals recurrence-risk niches in triple-negative breast cancer

Sicherheitsmeldung mit Schweregrad noch nicht bewertet. Technische Details im Tab „Originaltext“; empfohlene Schritte in der Checkliste.

Originaltext der Quelle (nicht übersetzt) – die deutsche Zusammenfassung findest du im Tab „Kurzfassung".

arXiv:2608.03145v1 Announce Type: new Abstract: Deep learning models can predict cancer recurrence from H&E stained slides, but the localized molecular states underlying these predictions remain largely obscured. Here, we developed an outcome informed spatial pathology framework in TNBC that integrates AI generated recurrence risk heatmaps with mass spectrometry based spatial proteomics. In a cohort of 156 patients, distribution based aggregation of high scoring patches achieved an AUC of 0.77 and a C-index of 0.77 in an independent test cohort. Bulk proteomics associated high image derived risk with cell cycle and genome maintenance programs and low risk with immune activation. High and low risk patches coexisted within the same tumor compartment and displayed distinct nuclear and architectural features, revealing intratumoral heterogeneity beyond tissue compartment identity. We then used the heatmaps as coordinate level guides to physically isolate and profile 46 AI defined tumor regions from two recurrence patients. Spatial proteomic profiling revealed a concordant molecular contrast across both patients: mitotic programs were enriched in high risk regions and immune and antigen presentation programs in low risk regions. A 13 protein composite derived from these spatial contrasts showed a trend toward poorer recurrence-free survival with increasing scores in an expanded cohort, while the corresponding transcript based composite stratified recurrence free survival in the independent METABRIC TNBC cohort. Integrating the protein composite with the H&E derived risk score …

Vollständiger Originalartikel ↗

• Betroffenheit im eigenen Stack prüfen: Versionen/Komponenten abgleichen.
• Originalquelle / Hersteller-Advisory lesen: https://arxiv.org/abs/2608.03145
• Verfügbaren Patch oder Workaround einspielen und dokumentieren.